Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

Yeztugo, a twice-a-year antiviral shot to prevent HIV, was approved by the Food and Drug Administration on Wednesday, marking ...

The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...

Individuals at risk for sexually acquired HIV have a new injectable option for preexposure prophylaxis (PrEP) with the US ...

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

The FDA approved lenacapavir (Yeztugo) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at ...

The Food and Drug Administration on Wednesday granted approval for Gilead Sciences’ twice-yearly injectable HIV prevention ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

Therapies called PrEP have been used to prevent HIV infections for years. In the United States, this may involve taking pills, such as a daily medication called Truvada, or getting shots ...

A twice-a-year shot to prevent HIV has the potential to greatly reduce ... such as Descovy or Truvada, said Eileen Scully, an associate professor of medicine who researches HIV at Johns Hopkins ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...